What is PCRX's P/E ratio?

PACIRA BIOSCIENCES, INC. (PCRX) currently trades at a P/E ratio of 106.28.

PACIRA BIOSCIENCES, INC. reports a Return on Equity (ROE) of 0.79%.

What is PCRX's dividend yield?

PACIRA BIOSCIENCES, INC. offers a dividend yield of 0.00%.

What is PCRX's Quality Score?

Our AI rates PCRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PCRX?

Our AI Timing Score for PCRX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PCRX belong to?

PACIRA BIOSCIENCES, INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

PCRX (NASDAQ) Stock Analysis | PACIRA BIOSCIENCES, INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PCRX AI Analysis Summary

Our AI summary for PCRX: PACIRA BIOSCIENCES, INC. (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 106.28, ROE of 0.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PCRX

PACIRA BIOSCIENCES, INC.

USD 26.41

-0.56 (-2.08%) Day Change

Watchlist Portfolio Compare Chart

106.28

P/E

0.58

D/E

0.8%

ROE

0.4%

ROA

0.00%

Div Yield

-0.94

PEG

PACIRA BIOSCIENCES, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 26.41 Price -0.56 (-2.08%) Day Change	NEWS SCORE: 88

PCRX, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	3060
Magic Formula Rank by ROE	3060
Magic Formula Rank by ROIC	2945
Price	26.41
PBV / Sector	1.62 / 3.22
Earning Per Share	0.13

PE / Sector	106.28 / 29.79
PEG or PE/Growth / Sector	-0.94 / 0.13
Average 1M Daily Value	12.38 M GREAT
Average 1W Daily Value	13.90 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	0.70 / 15.21
NPM Average (%) / Sector	-0.79 / -10.83
NPM Change Average (%) / Sector	-75.65 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	0.43 / 8.15
ROA Average (%) / Sector	-0.36 / 2.87
ROA Change Average (%) / Sector	-72.78 / 112.70
ROE (%) / Sector	0.79 / -1.02
ROE Average (%) / Sector	-0.82 / 8.35
ROE Change Average (%) / Sector	-90.23 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:18
Symbol	PCRX
Name	PACIRA BIOSCIENCES, INC.
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	39.35 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,061.21 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

Phone: 650 242 8052

Website: https://www.pacira.com

Employees: 825

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.